IKT PE Ratio & Valuation,Is IKT Overvalued

IKT Relative Valuation

IKT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, IKT is overvalued; if below, it's undervalued.

Historical Valuation

Inhibikase Therapeutics Inc (IKT) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -3.30. The fair price of Inhibikase Therapeutics Inc (IKT) is between -- to -- according to relative valuation methord.

Relative Value

Fair Zone

-----

Current Price：1.60

Fair

-2.64

0.00

EV/EBITDA

Inhibikase Therapeutics Inc. (IKT) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.

-1.63

EV/EBIT

Inhibikase Therapeutics Inc. (IKT) has a current EV/EBIT of -1.63. The 5-year average EV/EBIT is -1.65. The thresholds are as follows: Strongly Undervalued below -10.10, Undervalued between -10.10 and -5.88, Fairly Valued between 2.57 and -5.88, Overvalued between 2.57 and 6.80, and Strongly Overvalued above 6.80. The current Forward EV/EBIT of -1.63 falls within the Historic Trend Line -Fairly Valued range.

0.00

Inhibikase Therapeutics Inc. (IKT) has a current PS of 0.00. The 5-year average PS is 26.74. The thresholds are as follows: Strongly Undervalued below -45.06, Undervalued between -45.06 and -9.16, Fairly Valued between 62.64 and -9.16, Overvalued between 62.64 and 98.54, and Strongly Overvalued above 98.54. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-2.91

P/OCF

Inhibikase Therapeutics Inc. (IKT) has a current P/OCF of -2.91. The 5-year average P/OCF is -1.16. The thresholds are as follows: Strongly Undervalued below -5.48, Undervalued between -5.48 and -3.32, Fairly Valued between 0.99 and -3.32, Overvalued between 0.99 and 3.15, and Strongly Overvalued above 3.15. The current Forward P/OCF of -2.91 falls within the Historic Trend Line -Fairly Valued range.

-3.14

P/FCF

Inhibikase Therapeutics Inc. (IKT) has a current P/FCF of -3.14. The 5-year average P/FCF is -0.35. The thresholds are as follows: Strongly Undervalued below -2.30, Undervalued between -2.30 and -1.33, Fairly Valued between 0.63 and -1.33, Overvalued between 0.63 and 1.60, and Strongly Overvalued above 1.60. The current Forward P/FCF of -3.14 falls within the Strongly Undervalued range.

Inhibikase Therapeutics Inc (IKT) has a current Price-to-Book (P/B) ratio of 1.50. Compared to its 3-year average P/B ratio of -3.36 , the current P/B ratio is approximately -144.73% higher. Relative to its 5-year average P/B ratio of -1.15, the current P/B ratio is about -231.03% higher. Inhibikase Therapeutics Inc (IKT) has a Forward Free Cash Flow (FCF) yield of approximately -14.21%. Compared to its 3-year average FCF yield of -106.34%, the current FCF yield is approximately -86.64% lower. Relative to its 5-year average FCF yield of -79.54% , the current FCF yield is about -82.13% lower.

1.57

P/B

Median3y

-3.36

Median5y

-1.15

-14.21

FCF Yield

Median3y

-106.34

Median5y

-79.54

Competitors Valuation Multiple

The average P/S ratio for IKT's competitors is 0.00, providing a benchmark for relative valuation. Inhibikase Therapeutics Inc Corp (IKT) exhibits a P/S ratio of 0.00, which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of IKT increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of IKT in the past 1 year is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is Inhibikase Therapeutics Inc (IKT) currently overvalued or undervalued?

What is Inhibikase Therapeutics Inc (IKT) fair value?

IKT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Inhibikase Therapeutics Inc (IKT) is between to according to relative valuation methord.

How does IKT's valuation metrics compare to the industry average?

What is the current P/B ratio for Inhibikase Therapeutics Inc (IKT) as of Dec 16 2025?

As of Dec 16 2025, Inhibikase Therapeutics Inc (IKT) has a P/B ratio of 1.50. This indicates that the market values IKT at 1.50 times its book value.

What is the current FCF Yield for Inhibikase Therapeutics Inc (IKT) as of Dec 16 2025?

As of Dec 16 2025, Inhibikase Therapeutics Inc (IKT) has a FCF Yield of -14.21%. This means that for every dollar of Inhibikase Therapeutics Inc’s market capitalization, the company generates -14.21 cents in free cash flow.

What is the current Forward P/E ratio for Inhibikase Therapeutics Inc (IKT) as of Dec 16 2025?

As of Dec 16 2025, Inhibikase Therapeutics Inc (IKT) has a Forward P/E ratio of -2.53. This means the market is willing to pay $-2.53 for every dollar of Inhibikase Therapeutics Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Inhibikase Therapeutics Inc (IKT) as of Dec 16 2025?

As of Dec 16 2025, Inhibikase Therapeutics Inc (IKT) has a Forward P/S ratio of 0.00. This means the market is valuing IKT at $0.00 for every dollar of expected revenue over the next 12 months.

IKT Valuation